Review of patient-reported outcome measures in chronic hepatitis C

Health and Quality of Life Outcomes

Volumn 10, Issue , 2012, Pages

  Kleinman, Leah ^a   Mannix, Sally ^a   Yuan, Yong ^b   Kummer, Shannon ^a   L'Italien, Gilbert ^b   Revicki, Dennis ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Health related quality of life; Hepatitis C; Literature review; Patient reported outcomes

Indexed keywords

ALPHA2A INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO;

ANXIETY DISORDER; BIBLIOGRAPHIC DATABASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COGNITION; DEPRESSION; DRUG EFFICACY; EMBASE; FATIGUE; FLU LIKE SYNDROME; HEPATITIS C; INSOMNIA; MEASUREMENT; MEDLINE; MENTAL HEALTH; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT FORM 36; SYMPTOM; TREATMENT DURATION;

CLINICAL TRIALS AS TOPIC; HEALTH STATUS; HEPATITIS C, CHRONIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SELF REPORT;

EID: 84864775661     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-10-92     Document Type: Review

References (51)

1. Modi AA, Liang TJ. Hepatitis C: a clinical review. Oral Dis 2008, 14(1):10-14. 2803488, 18173443.
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002, 36(5 Suppl 1):S21-S29.
3. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35(3):704-708. 10.1053/jhep.2002.31311, 11870387.
4. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157(6):867-876. 10.1176/appi.ajp.157.6.867, 10831463.
5. Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA. Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illn 2006, 2(2):121-131.
6. Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB. Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med 2008, 23(12):1959-1965. 10.1007/s11606-008-0790-y, 2596521, 18807097.
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982. 10.1056/NEJMoa020047, 12324553.
8. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140(5):346-355.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965. 10.1016/S0140-6736(01)06102-5, 11583749.
10. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. Patients' experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns 2006, 62(1):148-155. 10.1016/j.pec.2005.06.019, 16098705.
11. Scientific Advisory Committee of the Medical Outcomes Trust Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002, 11(3):193-205. 10.1023/A:1015291021312, 12074258, Scientific Advisory Committee of the Medical Outcomes Trust.
12. Turner RR, Quittner AL, Parasuraman BM, Kallich JD, Cleeland CS. Patient-reported outcomes: instrument development and selection issues. Value Health 2007, 10(Suppl 2):S86-S93.
13. FDA Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009, 74(235):65132-65133. FDA.
14. Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol 2006, 12(29):4665-4672.
15. Dunne EA, Quayle E. The impact of latrogenically acquired Hepatitis C infection on the well-being and relationships of a group of Irish women. J Health Psychol 2001, 6(6):679-692. 10.1177/135910530100600606, 22049470.
16. Glacken M, Coates V, Kernohan G, Hegarty J. The experience of fatigue for people living with hepatitis C. J Clin Nurs 2003, 12(2):244-252. 10.1046/j.1365-2702.2003.00709.x, 12603557.
17. Glacken M, Kernohan G, Coates V. Diagnosed with Hepatitis C: a descriptive exploratory study. Int J Nurs Stud 2001, 38(1):107-116. 10.1016/S0020-7489(00)00046-8, 11137728.
18. Hopwood M, Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qual Health Res 2005, 15(5):635-646. 10.1177/1049732304273932, 15802540.
19. Hopwood M, Treloar C. Resilient coping: applying adaptive responses to prior adversity during treatment for hepatitis C infection. J Health Psychol 2008, 13(1):17-27. 10.1177/1359105307084308, 18086714.
20. Lang CA, Conrad S, Garrett L, Battistutta D, Cooksley WGE, Dunne MP, Macdonald GA. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. Journal of Pain and Symptom Management 2006, 31(4):335-344. 10.1016/j.jpainsymman.2005.08.016, 16632081.
21. Sheppard K, Hubbert A. The patient experience of treatment for hepatitis C. Gastroenterology nursing: the official journal of the Society of Gastroenterology Nurses and Associates 2006, 29(4):309-315.
22. Sutton R, Treloar C. Chronic illness experiences, clinical markers and living with hepatitis C. J Health Psychol 2007, 12(2):330-340. 10.1177/1359105307074278, 17284496.
23. Taylor-Young P, Hildebrandt E. The multidimensional burden of hepatitis C and its treatment: a case study. Gastroenterol Nurs 2009, 32(3):180-187. 10.1097/SGA.0b013e3181a80655, 19506434.
24. Teixeira PA, Schackman BR. Can urban methadone patients complete health utility assessments?. Patient Education and Counseling 2008, 71(2):302-307. 10.1016/j.pec.2008.01.010, 2361157, 18314295.
25. Treloar C, Holt M. Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aust Health Rev 2008, 32(3):570-576. 10.1071/AH080570, 18666886.
26. Zickmund SL, Bryce CL, Blasiole JA, Shinkunas L, LaBrecque DR, Arnold RM. Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. Eur J Gastroenterol Hepatol 2006, 18(4):381-388. 10.1097/00042737-200604000-00011, 16538109.
27. Fraser S, Treloar C. 'Spoiled identity' in hepatitis C infection: the binary logic of despair. Crit Pub Health 2006, 16(2):99-110.
28. Grow JM, Christopher SA. Breaking the silence surrounding hepatitis C by promoting self-efficacy: hepatitis C public service announcements. Qual Health Res 2008, 18(10):1401-1412. 10.1177/1049732308322603, 18832769.
29. Janke EA, McGraw S, Garcia-Tsao G, Fraenkel L. Psychosocial issues in hepatitis C: a qualitative analysis. Psychosomatics 2008, 49(6):494-501. 10.1176/appi.psy.49.6.494, 2743862, 19122126.
30. Schafer A, Scheurlen M, Felten M, Kraus MR. Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients. Eur J Gastroenterol Hepatol 2005, 17(12):1387-1394. 10.1097/00042737-200512000-00019, 16292094.
31. Grundy G, Beeching N. Understanding social stigma in women with hepatitis C. Nurs Stand (R Coll Nurs G B: 1987) 2004, 19(4):35-39.
32. Rowan PJ, Dunn NJ, El-Serag HB, Kunik ME. Views of hepatitis C virus patients delayed from treatment for psychiatric reasons. J Viral Hepat 2007, 14(12):883-889.
33. Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, Reindollar RW, Gane E, Patel K, Wintfeld N, Green J. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon (alpha)-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006, 21(2):406-412. 10.1111/j.1440-1746.2005.04059.x, 16509866.
34. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta EVA, Wintfeld N, Green J. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004, 40(4):675-681. 10.1016/j.jhep.2003.12.014, 15030985.
35. Nayman Alpat S, Usluer G, Yavuz H, Doyuk Kartal E, Erben N, Bal C, Ozgunes I. Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life. J Chemother 2008, 20(1):101-105.
36. Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacol Econ 2003, 21(5):341-349.
37. Perrillo R, Rothstein KD, Rubin R, Alam I, Imperial J, Harb G, Hu S, Klaskala W. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004, 11(2):157-165. 10.1046/j.1365-2893.2003.00482.x, 14996351.
38. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: Comparison between interferon-(alpha)-2a and interferon-(alpha)-2b. Clin Drug Investig 2006, 26(11):655-662. 10.2165/00044011-200626110-00005, 17163300.
39. Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998, 7(1):39-55.
40. Ware JE, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999, 30(2):550-555. 10.1002/hep.510300203, 10421667.
41. Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000, 9(5):499-508. 10.1023/A:1008960710415, 11190005.
42. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45(2):295-300. 10.1136/gut.45.2.295, 1727607, 10403745.
43. Leidy NK, Palmer C, Murray M, Robb J, Revicki DA. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder. Psychometric performance of four self-report measures. J Affect Disord 1998, 48(2-3):207-214.
44. Stewart AL, Ware JE, Sherbourne CD, Wells KB. Psychological distress/ well-being and cognitive functioning measures. Measuring Functioning and Well-being: The Medical Outcomes Study Approach 1992, 102-142. Duke University Press, Stewart AL, Ware JE, Durham NC, 381-394.
45. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, Ader D, Fries JF, Bruce B, Rose M. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007, 45(5 Suppl 1):S3-S11.
46. Christodoulou C, Junghaenel DU, DeWalt DA, Rothrock N, Stone AA. Cognitive interviewing in the evaluation of fatigue items: results from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res 2008, 17(10):1239-1246. 10.1007/s11136-008-9402-x, 2938781, 18850327.
47. DeWalt DA, Rothrock N, Yount S, Stone AA. Evaluation of item candidates: the PROMIS qualitative item review. Med Care 2007, 45(5 Suppl 1):S12-S21. 2810630, 17443114.
48. Revicki DA, Kawata AK, Harnam N, Chen WH, Hays RD, Cella D. Predicting EuroQol (EQ-5D) scores from the patient-reported outcomes measurement information system (PROMIS) global items and domain item banks in a United States sample. Qual Life Res 2009, 18(6):783-791. 10.1007/s11136-009-9489-8, 2704290, 19472072.
49. Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, Artinian L, Kim S, Lazarovici D, Jensen DM, Busuttil RW, Martin P. Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease-the LDQOL 1.0. Am J Gastroenterol 2000, 95(12):3552-3565.
50. Gutteling JJ, de Man RA, van der Plas SM, Schalm SW, Busschbach JJ, Darlington AS. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006, 23(11):1629-1635. 10.1111/j.1365-2036.2006.02934.x, 16696813.
51. van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, Schalm SW. The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. Qual Life Res 2004, 13(8):1469-1481.